The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bayer; Eisai; GlaxoSmithKline; Lilly; Mundipharma; Pfizer; PharmaMar
Research Funding - Adaptimmune (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Novartis; Pfizer; PharmaMar; ROVI
Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).
 
Martin McCabe
Consulting or Advisory Role - Amgen (Inst)
 
Laura Kirton
No Relationships to Disclose
 
Maria Khan
No Relationships to Disclose
 
Nicola Fenwick
No Relationships to Disclose
 
Sandra J. Strauss
Consulting or Advisory Role - Ceridwen Oncology; GlaxoSmithKline
 
Claudia Valverde
No Relationships to Disclose
 
Cristina Mata
No Relationships to Disclose
 
Nathalie Gaspar
Consulting or Advisory Role - Eisai; IPSEN
Travel, Accommodations, Expenses - Eisai
 
Roberto Luksch
No Relationships to Disclose
 
Alessandra Longhi
No Relationships to Disclose
 
Uta Dirksen
Consulting or Advisory Role - Ipsen; Lilly (Inst)
 
Marianne Phillips
No Relationships to Disclose
 
Akmal Safwat
No Relationships to Disclose
 
Hans Gelderblom
Research Funding - Daiichi (Inst); Deciphera (Inst); Ipsen (Inst); Novartis (Inst)
 
Thomas Kuehne
Consulting or Advisory Role - Amgen; Novartis; SOBI; UCB
Research Funding - Amgen (Inst); Novartis (Inst)
Expert Testimony - Amgen
 
Jukka Kanerva
Stock and Other Ownership Interests - Orion
Consulting or Advisory Role - Bayer
 
Andrew J. Westwood
No Relationships to Disclose
 
Stefano Ferrari
No Relationships to Disclose
 
Jeremy Whelan
No Relationships to Disclose
 
Keith Wheatley
Research Funding - Bayer (Inst); Bio-Cancer Treatment International (Inst); EUSA Pharma (Inst); Roche (Inst)